Remedy Plan Therapeutics is a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with acute leukemias and solid tumors. Our mission is to solve a decades-old medical-science puzzle: targeting NAD synthesis in cancer cells without damaging healthy cells. Our lead asset, RPT1G, is a novel, small-molecule NAMPT inhibitor designed for this purpose.